2019
A versatile flow-based assay for immunocyte-mediated cytotoxicity
Rabinovich PM, Zhang J, Kerr SR, Cheng BH, Komarovskaya M, Bersenev A, Hurwitz ME, Krause DS, Weissman SM, Katz SG. A versatile flow-based assay for immunocyte-mediated cytotoxicity. Journal Of Immunological Methods 2019, 474: 112668. PMID: 31525367, PMCID: PMC6891822, DOI: 10.1016/j.jim.2019.112668.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorCell NucleusCytotoxicity Tests, ImmunologicCytotoxicity, ImmunologicFlow CytometryHigh-Throughput Screening AssaysHumansImmunotherapy, AdoptiveKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMaleMelanomaMice, Inbred C57BLPredictive Value of TestsReceptors, Chimeric AntigenReproducibility of ResultsSkin NeoplasmsTime FactorsT-LymphocytesWorkflowConceptsCell-mediated cytotoxicityTumor-Infiltrating LymphocytesEffector cellsTarget cellsNK-92 cellsChimeric antigen receptorNuclear staining patternInfiltrating lymphocytesT cellsEffector nucleiFlow-based assayImmune systemFlow cytometryStaining patternAntigen receptorDead cellsKilling reactionCytotoxicityCell permeable dyeCellsAssaysCell mixturesNuclear proteinsNovel strategyCell proteins
2012
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, Fisher JK, Godes M, Pitter K, Kung AL, Walensky LD. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. Journal Of Clinical Investigation 2012, 122: 2018-2031. PMID: 22622039, PMCID: PMC3366394, DOI: 10.1172/jci46231.Peer-Reviewed Original ResearchConceptsBcl-2 family proteinsCell deathFamily proteinsPro-apoptotic Bcl-2 family proteinsBcl-2 protein familyBcl-2-interacting mediatorBcl-2 family pathwayHydrocarbon-stapled peptidesCell death mechanismsCancer cellsCellular lifeHematologic cancer cellsProtein familyDeath domainBH3 helixBim BH3Bim peptidesDeath mechanismsApoptotic blockadesApoptotic resistanceFamily pathwaySurvival pathwaysAntiapoptotic proteinsProapoptotic activityHuman AML xenograft model